Jones Trading Starts Coverage on Rein Therapeutics, Issues Buy Rating and $8 Target
Jones Trading has begun coverage of Rein Therapeutics (NASDAQ:RNTX) with a Buy rating and a price target of $8.00, implying substantial upside from the current share price of $1.43. The research note emphasizes the company’s commercial-stage dual-balloon catheter, RenovoCath, and recent clinical and regulatory milestones for lead drug candidate LTI…